Induction of CD152 (CTLA-4) and LAP (TGF-β1) in human Foxp3- CD4+ CD25- T cells modulates TLR-4 induced TNF-α production

Immunobiology

Volumn 218, Issue 3, 2013, Pages 427-434

  Boswell, Sandra ^a   Pathan, Ansar A ^b   Pereira, Stephen P ^a   Williams, Roger ^c   Behboudi, Shahriar ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c INSTITUTE OF HEPATOLOGY   (United Kingdom)

Author keywords

CD152; CD4+ T cells; LAP (TGF 1); TNF

Indexed keywords

CELL SURFACE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYPICAN 3; INTERLEUKIN 5 RECEPTOR ALPHA; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TYROSYLGLUTAMINYLLEUCYLTHREONYLALANYLARGINYLLEUCYLASPARAGYLMETHIONYLGLUTAMYLGLUTAMINYLLEUCYLLEUCYLGLUTAMINYLSERINE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CELL STIMULATION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOCYTOSIS; EXOCYTOSIS; FOXP3- CD4+ CD25+ T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; T LYMPHOCYTE;

ANTIGENS, CD4; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CTLA-4 ANTIGEN; ENDOCYTOSIS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GLYPICANS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873193482     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.05.028     Document Type: Article

References (35)

1. Ali N.A., Gaughan A.A., Orosz C.G., Baran C.P., McMaken S., Wang Y., Eubank T.D., Hunter M., Lichtenberger F.J., Flavahan N.A., Lawler J., Marsh C.B. Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1. PLoS One 2008, 3:e1914.
2. + T cells reduces Toll-like receptor 4 ligand-induced tumour necrosis factor-alpha production in a transforming growth factor-beta-dependent manner. Immunology 2011, 133:278.
3. Capurro M., Filmus J. Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res. 2005, 65:372. author reply 372.
4. Capurro M., Wanless I.R., Sherman M., Deboer G., Shi W., Miyoshi E., Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89.
5. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., Stuart D.I., van der Merwe P.A., Davis S.J. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201.
6. D'Souza-Schorey C., Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat. Rev. Mol. Cell Biol. 2006, 7:347.
7. Fecteau S., Basadonna G.P., Freitas A., Ariyan C., Sayegh M.H., Rothstein D.M. CTLA-4 up-regulation plays a role in tolerance mediated by CD45. Nat. Immunol. 2001, 2:58.
8. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 2008, 224:166.
9. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001, 11:19R.
10. Filmus J., Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol. Diagn. 2004, 8:207.
11. Finn P.W., He H., Wang Y., Wang Z., Guan G., Listman J., Perkins D.L. Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. J. Immunol. 1997, 158:4074.
12. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515.
13. Grozdanov P.N., Yovchev M.I., Dabeva M.D. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab. Invest. 2006, 86:1272.
14. Hryniewicz A., Boasso A., Edghill-Smith Y., Vaccari M., Fuchs D., Venzon D., Nacsa J., Betts M.R., Tsai W.P., Heraud J.M., Beer B., Blanset D., Chougnet C., Lowy I., Shearer G.M., Franchini G. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006, 108:3834.
15. Jenkins G.M., Frohman M.A. Phospholipase D: a lipid centric review. Cell. Mol. Life Sci. 2005, 62:2305.
16. Jones-Carson J., Fantuzzi G., Siegmund B., Dinarello C., Tracey K.J., Wang H., Fang F.C., Vazquez-Torres A. Suppressor alphabeta T lymphocytes control innate resistance to endotoxic shock. J. Infect. Dis. 2005, 192:1039.
17. Karumuthil-Melethil S., Perez N., Li R., Prabhakar B.S., Holterman M.J., Vasu C. Dendritic cell-directed CTLA-4 engagement during pancreatic beta cell antigen presentation delays type 1 diabetes. J. Immunol. 2010, 184:6695.
18. Kim H., Xu G.L., Borczuk A.C., Busch S., Filmus J., Capurro M., Brody J.S., Lange J., D'Armiento J.M., Rothman P.B., Powell C.A. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am. J. Respir. Cell Mol. Biol. 2003, 29:694.
19. Komori H., Nakatsura T., Senju S., Yoshitake Y., Motomura Y., Ikuta Y., Fukuma D., Yokomine K., Harao M., Beppu T., Matsui M., Torigoe T., Sato N., Baba H., Nishimura Y. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin. Cancer Res. 2006, 12:2689.
20. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995, 182:459.
21. Linsley P.S., Bradshaw J., Greene J., Peach R., Bennett K.L., Mittler R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996, 4:535.
22. Mead K.I., Zheng Y., Manzotti C.N., Perry L.C., Liu M.K., Burke F., Powner D.J., Wakelam M.J., Sansom D.M. Exocytosis of CTLA-4 is dependent on phospholipase D and ADP ribosylation factor-1 and stimulated during activation of regulatory T cells. J. Immunol. 2005, 174:4803.
23. Motomura Y., Ikuta Y., Kuronuma T., Komori H., Ito M., Tsuchihara M., Tsunoda Y., Shirakawa H., Baba H., Nishimura Y., Kinoshita T., Nakatsura T. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32:985.
24. Nakatsura T., Komori H., Kubo T., Yoshitake Y., Senju S., Katagiri T., Furukawa Y., Ogawa M., Nakamura Y., Nishimura Y. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin. Cancer Res. 2004, 10:8630.
25. Olsson C., Riesbeck K., Dohlsten M., Michaelsson E. CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J. Biol. Chem. 1999, 274:14400.
26. Perez N., Karumuthil-Melethil S., Li R., Prabhakar B.S., Holterman M.J., Vasu C. Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+)-adaptive regulatory T cell generation. J. Immunol. 2008, 180:6566.
27. Perkins D., Wang Z., Donovan C., He H., Mark D., Guan G., Wang Y., Walunas T., Bluestone J., Listman J., Finn P.W. Regulation of CTLA-4 expression during T cell activation. J. Immunol. 1996, 156:4154.
28. Salomon B., Bluestone J.A. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 2001, 19:225.
29. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 2006, 24:65.
30. Thompson C.B., Allison J.P. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997, 7:445.
31. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541.
32. Valk E., Rudd C.E., Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol. 2008, 29:272.
33. + T lymphocytes. J. Immunol. 2002, 169:6231.
34. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995, 270:985.
35. + regulatory cells. J. Immunol. 2006, 176:3321.